Companies /Healthcare

Procept BioRobotics Corp

NASDAQ: PRCT Medical Devices
$25.75
▲ $0.57 (+2.26%) today
Markets closed · 6:08pm ET

PRCT at a Glance

Valuation
Market cap
$1.4B
Profitability
Revenue (TTM)
$352.3M
Profit margin
-32.6%
EPS (TTM)
$-2.02
Price
52-week range
$17 – $38
Street target
$22.75

Headquartered in San Jose, CA Fiscal year ends December NASDAQ: PRCT procept-biorobotics.com

About Procept BioRobotics

PROCEPT BioRobotics is a surgical robotics company focused on urology. It manufactures the AQUABEAM and HYDROS Robotic Systems, which deliver Aquablation therapy. HYDROS is described as the only AI-powered robotic technology for this therapy.

Aquablation therapy is designed to treat lower urinary tract symptoms (LUTS) in men caused by benign prostatic hyperplasia (BPH). It aims to deliver effective, safe and durable outcomes independent of prostate size and shape or surgeon experience. BPH affects approximately 40 million men in the United States.

The business model combines three revenue streams:
- Capital system sales and rentals.
- Recurring per-procedure handpieces and other consumables, which make up the largest revenue stream.
- Service revenue from the installed base.

The company sells in the U.S. and internationally. At the end of Q3 2026 its U.S. installed base was 858 systems, and it is actively replacing legacy AquaBeam systems with HYDROS. The company cites approximately 250 peer-reviewed publications supporting Aquablation. It is running the WATER IV randomized trial comparing Aquablation with radical prostatectomy in prostate cancer, with data expected in the first half of 2027. Updated

PRCT Coverage

Frequently Asked Questions

What does Procept BioRobotics do?

PROCEPT BioRobotics is a surgical robotics company focused on urology. It manufactures the AQUABEAM and HYDROS Robotic Systems, which deliver Aquablation therapy.

What is the PRCT stock price target?

The Wall Street consensus 12-month price target for PRCT is $22.75.